News FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis pharminent August 28, 2026
Clinical Data New data could widen use of AstraZeneca, Amgen immune disease drug pharminent August 27, 2026
Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026
News FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer pharminent August 26, 2026
M&A / Deals Metsera backers establish new biotech armed with China-licensed immunology asset pharminent August 26, 2026
News FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease pharminent August 25, 2026
M&A / Deals China’s Haisco forms immunology biotech with up to $1.5B from American VCs pharminent August 25, 2026
Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026
Regulatory FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial pharminent August 25, 2026
News Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 Billion pharminent August 24, 2026
Regulatory Capricor’s Duchenne therapy has new life after FDA grants 3-month extension pharminent August 24, 2026
M&A / Deals Roche commits to lean-mass preservation with Hanmi obesity deal pharminent August 24, 2026
Regulatory Johnson & Johnson’s multiple myeloma treatment secures EC approval pharminent August 24, 2026
News Johnson & Johnson Wins EU Approval for Tecvayli-Daratumumab in Second-Line Myeloma pharminent August 21, 2026
Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026
Manufacturing Roche commits $750m to double Oregon-based US manufacturing capacity pharminent August 21, 2026
News Regeneron’s Pasatru Wins Full FDA Approval for Ultra-Rare ‘Stone Man Disease’ pharminent August 20, 2026
Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026
Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026
Clinical Data Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future pharminent August 20, 2026
Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
News Moderna and Merck’s Personalized Melanoma Vaccine Scores Historic Phase 3 Win pharminent August 19, 2026
M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026
News Amylyx’s Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric Hypoglycemia pharminent August 18, 2026
News AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline pharminent August 17, 2026
M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026